After breast cancer surgery, test neratinib plus trastuzumab
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, age 18–70
- Your cancer is invasive breast cancer that is hormone-receptor positive and HER2 positive
- You finished at least 4 cycles of trastuzumab and pertuzumab before surgery, and there’s no metastasis (cancer spread) afterward
- After neoadjuvant treatment, you have residual cancer class 0 or 1, and randomization starts within 12 weeks of the first surgery
- Your heart strength is good (left heart pump ejection fraction is at least 50%) and hasn’t dropped too much
- Your blood counts and liver/kidney labs are within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
This trial tests whether taking neratinib for one extra year can reduce the risk of breast cancer returning in women who had a complete response (no cancer found) after initial treatment but still have high-risk features. It is for women with HER2-positive early breast cancer.
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.